Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Dec 15;10(12):2160.
doi: 10.3390/vaccines10122160.

Immunogenicity of Catch-Up Immunization with Conventional Inactivated Polio Vaccine among Japanese Adults

Shinji Fukushima  1 , Takashi Nakano  2 , Hiroyuki Shimizu  3 , Atsuo Hamada  1
Affiliations

Immunogenicity of Catch-Up Immunization with Conventional Inactivated Polio Vaccine among Japanese Adults

Shinji Fukushima et al. Vaccines (Basel). .

Abstract

Most Japanese adults are vaccinated twice with the Sabin trivalent oral polio vaccine. Booster vaccination is recommended for Japanese travelers to polio-endemic/high-risk countries. We assessed the catch-up immunization of healthy Japanese adults aged ≥20 years with two doses of standalone conventional inactivated polio vaccine (cIPV). Immunogenicity was evaluated by serum neutralization titers (pre-booster vaccination, 4-6 weeks after each vaccination) against type 1, 2, and 3 poliovirus strains. The participants were 61 healthy Japanese adults (26 men/35 women; mean age ± standard deviation age 35.8 ± 8.0 years). Seropositivity rates (percentage of participants with anti-poliovirus antibody titers ≥1:8) pre-vaccination were 88.5%, 95.1%, and 52.5% for Sabin strains (type 1, 2, and 3); 72.1%, 93.4%, and 31.1% for virulent poliovirus strains (type 1: Mahoney; type 2: MEF-1; and type 3: Saukett); and 93.4%, 93.4%, 93.4%, and 88.5% for type 2 vaccine-derived poliovirus strains (SV3128, SV3130, 11,196, and 11,198). After one cIPV dose, all seropositivity rates increased to 98.4-100.0%. After two cIPV doses, the seropositivity rates reached 100% for all strains. cIPV was well tolerated, with no safety concerns. Catch-up immunization with standalone cIPV induced robust immune responses in Japanese adults, indicating that one booster dose boosted serum-neutralizing antibodies to many strains.

Keywords: catch-up immunization; conventional inactivated polio vaccine; immunogenicity; trivalent oral polio vaccine.

PubMed Disclaimer

Conflict of interest statement

S. Fukushima, A. Hamada, and H. Shimizu declare no conflicts of interest associated with this study and manuscript. T. Nakano received honoraria from Daiichi Sankyo Co. and Sanofi K.K. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript; or in the decision to publish the results.

Similar articles

See all similar articles

Cited by

References

    1. Global Polio Eradication Initiative Wild Poliovirus List. [(accessed on 25 October 2022)]. Available online: https://polioeradication.org/polio-today/polio-now/wild-poliovirus-list/
    1. World Health Organization WHO Statement on the Meeting of the International Health Regulations Emergency Committee Concerning the International Spread of Wild Poliovirus. 2014. [(accessed on 30 November 2022)]. Available online: https://www.who.int/news/item/05-05-2014-who-statement-on-the-meeting-of....
    1. World Health Organization Statement of the Thirty-Third Polio IHR Emergency Committee. 2022. [(accessed on 30 November 2022)]. Available online: https://www.who.int/news/item/01-11-2022-statement-of-the-thirty-third-p....
    1. Patel M., Zipursky S., Orenstein W., Garon J., Zaffran M. Polio endgame: The global introduction of inactivated polio vaccine. Expert Rev. Vaccines. 2015;14:749–762. doi: 10.1586/14760584.2015.1001750. - DOI - PubMed
    1. Greene S.A., Ahmed J., Datta S.D., Burns C.C., Quddus A., Vertefeuille J.F., Wassilak S.G.F. Progress toward polio eradication–worldwide, January 2017–March 2019. Morb. Mortal. Wkly. Rep. 2019;68:458–462. doi: 10.15585/mmwr.mm6820a3. - DOI - PMC - PubMed

LinkOut - more resources